GlassScriptPhysician profile
Paul L Smith
NPI 1063480473
$5,086.48
in general payments reported to CMS, 2019-2025
33 companies · $978 in 2025
The $978 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $328 · 2021: $581 · 2022: $1,238 · 2023: $912 · 2024: $807 · 2025: $978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,666 · Education: $29.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,666.39 |
| Education | $29.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $981.22 | 2020-2025 | Dupixent, Libtayo |
| Abbvie INC. | $681.21 | 2019-2025 | Skyrizi |
| Janssen Biotech, INC. | $591.09 | 2020-2025 | Tremfya, Simponi, Remicade |
| Genzyme Corporation | $416.11 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $407.87 | 2020-2025 | Blu-U, Odomzo |
| Ucb, INC. | $297.67 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $239.62 | 2022-2025 | Opzelura |
| Amgen INC. | $199.76 | 2021-2023 | Otezla |
| Galderma Laboratories, L.P. | $189.66 | 2019-2025 | Aklief, Nemluvio |
| Novartis Pharmaceuticals Corporation | $176.43 | 2020-2025 | |
| Lilly USA, LLC | $94.08 | 2019-2024 | Taltz, Olumiant |
| Pfizer INC. | $89.38 | 2019-2021 | |
| Leo Pharma INC. | $68.87 | 2022-2023 | Adbry |
| Verrica Pharmaceuticals INC. | $65.75 | 2025 | Ycanth |
| Almirall LLC | $63.61 | 2022-2024 | Seysara |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $59.94 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.90 | 2019-2024 | Jublia, Cabtreo, Arazlo |
| E.R. Squibb & Sons, L.L.C. | $58.10 | 2024 | Sotyktu |
| Ani Pharmaceuticals, INC. | $44.42 | 2025 | Purified Cortrophin Gel |
| Celgene Corporation | $39.09 | 2019 | |
| Celltrion USA INC. | $29.53 | 2023 | Yuflyma |
| Arcutis Biotherapeutics, INC. | $23.99 | 2024 | Zoryve |
| Kyowa Kirin, INC. | $23.62 | 2024 | Poteligeo |
| Botanix Sb INC | $23.19 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $21.18 | 2019 | |
| Vyne Pharmaceuticals INC. | $19.63 | 2020 | |
| Mindera Corp | $19.57 | 2025 | |
| Journey Medical Corporation | $19.28 | 2023 | |
| Mission Pharmacal Company | $18.85 | 2019 | |
| Lnhc, INC | $18.02 | 2025 | Zelsuvmi |
| Strata Skin Sciences, INC. | $17.42 | 2025 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $16.34 | 2025 | Valchlor |
| Smith+Nephew, INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.